Literature DB >> 21325600

Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma.

Yu Sawada1, Ryosuke Hino, Kayo Hama, Shun Ohmori, Haruna Fueki, Shigenori Yamada, Shoko Fukamachi, Makiko Tajiri, Rieko Kubo, Manabu Yoshioka, Daiki Nakashima, Kazunari Sugita, Ryutaro Yoshiki, Takatoshi Shimauchi, Tomoko Mori, Kunio Izu, Miwa Kobayashi, Motonobu Nakamura, Yoshiki Tokura.   

Abstract

Cutaneous involvement is seen in ~ 50% of adult T-cell leukemia/lymphoma (ATLL) patients. We investigated the association between skin eruption type and prognosis in 119 ATLL patients. ATLL eruptions were categorized into patch (6.7%), plaque (26.9%), multipapular (19.3%), nodulotumoral (38.7%), erythrodermic (4.2%), and purpuric (4.2%) types. When the T stage of the tumor-node-metastasis-blood (TNMB) classification of mycosis fungoides/Sézary syndrome was applied to ATLL staging, 16.0% were T1, 17.7% T2, 38.7% T3, and 4.2% T4, and the remaining 23.5% were of the multipapular and purpuric types. For the patch type, the mean survival time (median survival time could not be estimated) was 188.4 months. The median survival times (in months) for the remaining types were as follows: plaque, 114.9; multipapular, 17.3; nodulotumoral, 17.3; erythrodermic, 3.0; and purpuric, 4.4. Kaplan-Meier curves of overall survival showed that the erythrodermic type had the poorest prognosis, followed by the nodulotumoral and multipapular types. The patch and plaque types were associated with better survival rates. Multivariate analysis demonstrated that the hazard ratios of the erythrodermic and nodulotumoral types were significantly higher than that of the patch type, and that the eruption type is an independent prognostic factor for ATLL. The overall survival was worse as the T stage became more advanced: the multipapular type and T2 were comparable, and the purpuric type had a significantly poorer prognosis than T1.

Entities:  

Mesh:

Year:  2011        PMID: 21325600     DOI: 10.1182/blood-2010-11-316794

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Adult T-cell leukemia/lymphoma.

Authors:  Robbie L Graham; Micah Burch; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-07

2.  Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis.

Authors:  Fernando Abollo-Jiménez; Elena Campos-Sánchez; Amparo Toboso-Navasa; Carolina Vicente-Dueñas; Inés González-Herrero; Esther Alonso-Escudero; Marcos González; Víctor Segura; Oscar Blanco; José Angel Martínez-Climent; Isidro Sánchez-García; César Cobaleda
Journal:  Cell Cycle       Date:  2014-03-25       Impact factor: 4.534

Review 3.  Updates in lymph node and skin pathology of adult T-cell leukemia/lymphoma, biomarkers, and beyond.

Authors:  Brian D Adkins; Juan C Ramos; Meghan Bliss-Moreau; Alejandro A Gru
Journal:  Semin Diagn Pathol       Date:  2019-12-20       Impact factor: 3.464

4.  Recurrent Facial Erythema with Cytotoxic T Cell Infiltration as a Possible Reactive Eruption in a Human T-Cell Lymphotropic Virus Type 1 Carrier.

Authors:  Yasuhiro Kaneko; Kazuki Tatsuno; Toshiharu Fujiyama; Taisuke Ito; Yoshiki Tokura
Journal:  Case Rep Dermatol       Date:  2015-05-20

5.  Multifaceted adult T-cell leukemia/lymphoma in India: a case series.

Authors:  Anza Khader; Mohamed Shaan; Sunitha Balakrishnan; Betsy Ambooken; Kunnummel Muhammed; Uma Rajan
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

Review 6.  Viral Oncology: Molecular Biology and Pathogenesis.

Authors:  Uyen Ngoc Mui; Christopher T Haley; Stephen K Tyring
Journal:  J Clin Med       Date:  2017-11-29       Impact factor: 4.241

7.  Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil.

Authors:  Pedro Dantas Oliveira; Ítala Gomes; Victor Hugo Gomes Souza; Ernesto Cunha Pires; Glória Bomfim Arruda; Achiléa Bittencourt
Journal:  Rev Bras Hematol Hemoter       Date:  2016-10-22

8.  Cell Adhesion Molecule 1 (CADM1) Is an Independent Prognostic Factor in Patients with Cutaneous Squamous Cell Carcinoma.

Authors:  Natsuko Saito-Sasaki; Yu Sawada; Etsuko Okada; Motonobu Nakamura
Journal:  Diagnostics (Basel)       Date:  2021-05-04

9.  Clinical Trials and Treatment of ATL.

Authors:  Kunihiro Tsukasaki; Kensei Tobinai
Journal:  Leuk Res Treatment       Date:  2012-01-16

10.  Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey.

Authors:  Kisato Nosaka; Masako Iwanaga; Yoshitaka Imaizumi; Kenji Ishitsuka; Kenichi Ishizawa; Yoji Ishida; Masahiro Amano; Takashi Ishida; Naokuni Uike; Atae Utsunomiya; Koichi Ohshima; Kazuhiro Kawai; Junji Tanaka; Yoshiki Tokura; Kensei Tobinai; Toshiki Watanabe; Kaoru Uchimaru; Kunihiro Tsukasaki
Journal:  Cancer Sci       Date:  2017-10-08       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.